1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 04 JANUARY 2016

CNS Drug News 04 JANUARY 2016

  • January 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Compliance Will Be Key In Future CNS Medication
Industry Trend Analysis - LID Success Will Allow Adamas To Grow
Industry Brief - Intec Receives IRB Approval To Initiate AP-COLD Phase III PD Trial
Industry Brief - ADS-5102 Phase III EASE LID Trial Meets Primary Endpoint
Industry Brief - Enrolment Begins In ND0612H Phase II Trial In Advanced PD
Industry Trend Analysis - Laquinimod Viability In Doubt
Industry Brief - GeNeuro Initiates GNbAC1 Phase IIb Trial In RRMS
Industry Trend Analysis - Fast Track Designation Supporting Mid-term Operations
Industry Brief - Aquinnah Secures USD5mn Investment From Takeda To Advance ALS Therapies
Industry Brief - Radicut Approved In South Korea For ALS
Industry Brief - Sanbio/Sunovion Begin Regenerative Therapy Phase IIb Trial For Chronic Stroke
Industry Brief - ICT Begins Enrolment For ITI-007 Phase III Trials In Bipolar Depression
Industry Brief - Pristiq Phase III Paediatric MDD Study Misses Primary Endpoint
Industry Brief - EMA Accepts Fanaptum MAA For Schizophrenia In Adults
Industry Brief - Egalet Submits Arymo NDA In US
Industry Brief - Antares Gains FDA Sumatriptan Approval
Industry Brief - FDA Approves Merck's Bridion For Reversal Of NMB
Industry Brief - Hikma Gains FDA Neostigmine Approval
Industry Brief - CHMP Accepts AcelRx' ARX-04 MAA For Centralised Review
Industry Brief - Depomed Acquires Certain Rights To Cebranopadol From Grunenthal
Industry Brief - First Patient Enrolled In Phase III Efficacy Trial Of CAM2038
Industry Brief - Neurelis Receives FDA ODD For NRL-1 In Acute Repetitive Seizures
Industry Brief - FDA Accepts Zogenix' IND For ZX003 Phase III Trial In Dravet Syndrome
Industry Brief - Interim Results From Alexza AZ-002 Phase IIa Study In ARS
Industry Trend Analysis - ULS Indication Will Not Revitalise Xeomin
Industry Brief - Ionis Earns Milestone In Neurology Collaboration With Biogen
Industry Brief - Cantabio/Gardedam Complete Merger

Table Of Contents

CNS Drug News 04 JANUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.